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Recent clinical trials regarding the intravitreal injection
of antivascular endothelial growth factor (VEGF) agents
(ranibizumab, bevacizumab, pegaptanib, and aﬂibercept)
have shown excellent results in the treatment of angiogenic
pathologies including choroidal neovascularization, macular
edema, proliferative diabetic retinopathy, and neovascular
glaucoma. Ranibizumab (Lucentis, Genectech, San Fran-
cisco), a fragment of a humanized monoclonal antibody
against all VEGF isoforms, is beneﬁcial in the treatment of
choroidalneovascularizationsecondarytoage-relatedmacu-
lar degeneration (AMD). Bevacizumab (Avastin, Genentech,
San Francisco), a humanized, recombinant monoclonal IgG
antibody that binds and inhibits all VEGF isoforms, has been
approved as an adjuvant agent for the treatment of colorectal
carcinoma and has also been increasingly used as an oﬄabel
therapyintheﬁeldofophthalmology.Pegaptanib(Mucugen,
Pﬁzer, New York) is a 28-base ribonucleic acid aptamer,
covalently linked to two branched 20-kD polyethylene glycol
moieties, that wasdeveloped to bind andblock theactivity of
extracellular VEGF, speciﬁcally the 165-aminoacid isoform
(VEGF165). Aﬂibercept (VEGF Trap-Eye, Regeneron, New
York; Bayer, Berlin, Germany) is a 115-kDa recombinant
fusion protein consisting of the VEGF-binding domains of
human VEGF receptors 1 and 2 fused to the Fc domain of
human immunoglobulin-G1.
Intraocular injections of anti-VEGF drug are considered
to be an eﬀective treatment for macular edema after retinal
vein occlusion. The recent reports may lead to a shift in
treatment paradigm for diabetic macular edema, from laser
photocoagulation to newer approaches using anti-VEGF
drugs. There have been several well-publicized prospec-
tive, randomized studies that demonstrated the eﬃcacy of
intravitreal injection of anti-VEGF drugs for patients with
AMD. Adjuvant bevacizumab for neovascular glaucoma may
prevent further peripheral anterior synechiae formation, and
it is likely to open up a therapeutic window for a panretinal
photocoagulation and trabeculectomy. Intravitreal injection
of bevacizumab (IVB) results in a substantial decrease in
bleeding from the retinal vessels or new vessels during
a standard vitrectomy. IVB has also been reported to be
eﬀective for inducing the regression of new vessels in
proliferative diabetic retinopathy. The use of bevacizumab in
stage 4 or 5 retinopath of prematurity (ROP) is to reduce the
plus sign to help reduce hemorrhage during the subsequent
vitrectomy. Some authors reported cases of resolution of
stage 4A ROP after bevacizumab injection.
This special issue of anti-VEGF agents comprises ﬁve
review articles and two research articles. The review article
of K. Kimoto and T. Kubota is a concise overview on the
application of anti-VEGF agents in angiogenic pathologies
and vascular permeability. The review article of A. Willard
and I. Herman describes the mechanisms behind diabetic
retinal complications, current research supporting anti-
VEGF medications, and future therapeutic directions. The2 Journal of Ophthalmology
review of P. Keane and S. Sadda summarizes the history
of anti-VEGF drugs and presents a guide for clinicians on
the development of anti-VEGF therapies for intraocular use.
The review article of Y. Park et al. describes the treatment
possibilities including combination therapy for age-related
macular degeneration. The review article of I. Zampros et al.
summarizes the current literature regarding the eﬀectiveness
of current anti-VEGF treatment for neovascular AMD. The
two research articles describe (i) bevacizumab injection in
patients with age-related macular degeneration associated
with poor initial visual acuity, (ii) photodynamic therapy
combined with intravitreal ranibizumab for exudative age-
related macular degeneration. We sincerely hope that the
present volume of a special issue series may provide useful
information to understand the mechanisms of the clinical
eﬀectsofanti-VEGFdrugtherapy,aswellastheevaluationof
their outcomes for the readers in Journal of Ophthalmology.
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